Home › Companies › PTC Therapeutics, Inc. › 2025-2026

PTC Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and PTC Therapeutics, Inc.’s Form 8-K, filed June 5, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

6Reported items
347Asset managers
3,022Fund votes
June 2, 2026Meeting date

Results at a glance

Meeting of June 2, 2026: 4 items on PTC Therapeutics, Inc.’s Form 8-K, filed June 5, 2026: 4 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore PTC Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by PTC Therapeutics, Inc.

These tallies are PTC Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PTC Therapeutics, Inc. — official shareholder meeting results, meeting held June 2, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Jessica Chutter	71,945,515	--	--	737,780	3,858,311	99%	Not verified	—
Elect Director: Matthew B. Klein, M.D., M.S., F.A.C.S.	71,550,878	--	--	1,132,417	3,858,311	98%	Not verified	—
Elect Director: Stephanie S. Okey, M.S.	68,902,707	--	--	3,780,588	3,858,311	95%	Not verified	—
Elect Director: Jerome B. Zeldis, M.D., Ph.D.	69,821,943	--	--	2,861,352	3,858,311	96%	Not verified	—

Source: PTC Therapeutics, Inc., Form 8-K, filed with the SEC on June 5, 2026 — read the filing on EDGAR.

How asset managers voted at the PTC Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 347 asset managers that disclosed a PTC Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of PTC Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Jerome B. Zeldis, M.D., Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 69,821,943WITHHELD: 2,861,352

Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: Election of Four Class I Directors: Jerome B. Zeldis, M.D., Ph.D.

PTC Therapeutics, Inc.’s own tally for this item (“Elect Director: Jerome B. Zeldis, M.D., Ph.D.”): 69,821,943 for, 2,861,352 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 36,152,747 for, 630,941 withheld, 268,996 abstained.

FOR

FOR: 36,152,747ABSTAIN: 268,996WITHHOLD: 630,941

Largest asset managers voting on “Election of Four Class I Directors: Jerome B. Zeldis, M.D., Ph.D.” at PTC Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	10,913,366	20	0	For
BlackRock	8,919,225	0	0	For
Fidelity	3,183,248	0	0	For
State Street	2,643,965	0	146	For
JANUS INVESTMENT FUND	1,908,579	0	0	For
Manager Directed Portfolios	988,439	0	0	For
Charles Schwab	677,090	0	0	For
Invesco	663,622	0	0	For
TIAA	628,538	0	0	For
FRANKLIN STRATEGIC SERIES	488,115	0	0	For
Lord Abbett	385,360	0	0	For
Bridge Builder Trust	337,477	0	0	For
T. Rowe Price	0	0	324,181	Withhold
Jackson National	299,094	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	66,033	218,556	0	Mixed
Hartford	262,612	0	0	For
Dimensional	225,758	0	0	For
Voya	220,168	0	0	For
Equitable	132,509	0	59,080	Mixed
Loomis Sayles	176,905	0	0	For
Federated Hermes	148,171	0	0	For
Columbia Threadneedle	147,623	0	0	For
Russell Investments	138,672	0	0	For
DRIEHAUS MUTUAL FUNDS	137,087	0	0	For
QUANTITATIVE MASTER SERIES LLC	127,843	0	0	For

Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.

2. Elect Director: Jessica Chutter

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 71,945,515WITHHELD: 737,780

Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: Election of Four Class I Directors: Jessica Chutter

PTC Therapeutics, Inc.’s own tally for this item (“Elect Director: Jessica Chutter”): 71,945,515 for, 737,780 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 36,682,283 for, 106,772 withheld, 263,629 abstained.

FOR

FOR: 36,682,283ABSTAIN: 263,629WITHHOLD: 106,772

Largest asset managers voting on “Election of Four Class I Directors: Jessica Chutter” at PTC Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	10,913,382	4	For
BlackRock	8,919,225	0	For
Fidelity	3,183,248	0	For
State Street	2,644,111	0	For
JANUS INVESTMENT FUND	1,908,579	0	For
Manager Directed Portfolios	988,439	0	For
Charles Schwab	677,090	0	For
Invesco	663,622	0	For
TIAA	628,538	0	For
FRANKLIN STRATEGIC SERIES	488,115	0	For
Lord Abbett	385,360	0	For
Bridge Builder Trust	337,477	0	For
T. Rowe Price	324,181	0	For
Jackson National	299,094	0	For
TRUST FOR PROFESSIONAL MANAGERS	66,033	218,556	Mixed
Hartford	262,612	0	For
Dimensional	225,758	0	For
Voya	220,168	0	For
Equitable	191,589	0	For
Loomis Sayles	176,905	0	For
Federated Hermes	148,171	0	For
Columbia Threadneedle	147,623	0	For
Russell Investments	138,672	0	For
DRIEHAUS MUTUAL FUNDS	137,087	0	For
QUANTITATIVE MASTER SERIES LLC	127,843	0	For

Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.

3. Elect Director: Matthew B. Klein, M.D., M.S., F.A.C.S.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 71,550,878WITHHELD: 1,132,417

Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: Election of Four Class I Directors: Matthew B. Klein, M.D., M.S., F.A.C.S.

PTC Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew B. Klein, M.D., M.S., F.A.C.S.”): 71,550,878 for, 1,132,417 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 36,682,135 for, 106,918 withheld, 263,631 abstained.

FOR

FOR: 36,682,135ABSTAIN: 263,631WITHHOLD: 106,918

Largest asset managers voting on “Election of Four Class I Directors: Matthew B. Klein, M.D., M.S., F.A.C.S.” at PTC Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	10,913,380	6	0	For
BlackRock	8,919,225	0	0	For
Fidelity	3,183,248	0	0	For
State Street	2,643,965	0	146	For
JANUS INVESTMENT FUND	1,908,579	0	0	For
Manager Directed Portfolios	988,439	0	0	For
Charles Schwab	677,090	0	0	For
Invesco	663,622	0	0	For
TIAA	628,538	0	0	For
FRANKLIN STRATEGIC SERIES	488,115	0	0	For
Lord Abbett	385,360	0	0	For
Bridge Builder Trust	337,477	0	0	For
T. Rowe Price	324,181	0	0	For
Jackson National	299,094	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	66,033	218,556	0	Mixed
Hartford	262,612	0	0	For
Dimensional	225,758	0	0	For
Voya	220,168	0	0	For
Equitable	191,589	0	0	For
Loomis Sayles	176,905	0	0	For
Federated Hermes	148,171	0	0	For
Columbia Threadneedle	147,623	0	0	For
Russell Investments	138,672	0	0	For
DRIEHAUS MUTUAL FUNDS	137,087	0	0	For
QUANTITATIVE MASTER SERIES LLC	127,843	0	0	For

Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.

4. Elect Director: Stephanie S. Okey, M.S.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 7 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 68,902,707WITHHELD: 3,780,588

Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: Election of Four Class I Directors: Stephanie S. Okey, M.S.

PTC Therapeutics, Inc.’s own tally for this item (“Elect Director: Stephanie S. Okey, M.S.”): 68,902,707 for, 3,780,588 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 36,059,274 for, 724,415 withheld, 268,996 abstained.

FOR

FOR: 36,059,274ABSTAIN: 268,996WITHHOLD: 724,415

Largest asset managers voting on “Election of Four Class I Directors: Stephanie S. Okey, M.S.” at PTC Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	10,900,994	20	12,373	For
BlackRock	8,919,225	0	0	For
Fidelity	3,183,248	0	0	For
State Street	2,644,111	0	0	For
JANUS INVESTMENT FUND	1,908,579	0	0	For
Manager Directed Portfolios	988,439	0	0	For
Charles Schwab	677,090	0	0	For
Invesco	663,622	0	0	For
TIAA	628,538	0	0	For
FRANKLIN STRATEGIC SERIES	488,115	0	0	For
Lord Abbett	385,360	0	0	For
Bridge Builder Trust	337,477	0	0	For
T. Rowe Price	0	0	324,181	Withhold
Jackson National	299,094	0	0	For
TRUST FOR PROFESSIONAL MANAGERS	66,033	218,556	0	Mixed
Hartford	262,612	0	0	For
Dimensional	225,758	0	0	For
Voya	220,168	0	0	For
Equitable	132,509	0	59,080	Mixed
Loomis Sayles	176,905	0	0	For
Federated Hermes	148,171	0	0	For
Columbia Threadneedle	147,623	0	0	For
Russell Investments	138,672	0	0	For
DRIEHAUS MUTUAL FUNDS	137,087	0	0	For
QUANTITATIVE MASTER SERIES LLC	127,843	0	0	For

Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.

5. Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the…

No official match Fund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99% Fund and manager reports combined; may count the same shares twice · no official result

FOR

Details: description as filed, votes by 346 asset managers

Description as filed by funds: Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 109 asset managers voting on “Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described ” at PTC Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	10,913,378	8	For
BlackRock	8,919,225	0	For
Fidelity	3,183,248	0	For
State Street	2,644,111	0	For
JANUS INVESTMENT FUND	1,908,579	0	For
Manager Directed Portfolios	988,439	0	For
Charles Schwab	677,090	0	For
Invesco	663,622	0	For
TIAA	628,538	0	For
FRANKLIN STRATEGIC SERIES	488,115	0	For
Lord Abbett	385,360	0	For
Bridge Builder Trust	337,477	0	For
T. Rowe Price	324,181	0	For
Jackson National	299,094	0	For
TRUST FOR PROFESSIONAL MANAGERS	284,589	0	For
Hartford	262,612	0	For
Dimensional	225,758	0	For
Voya	220,168	0	For
Equitable	191,589	0	For
Loomis Sayles	176,905	0	For
Federated Hermes	148,171	0	For
Columbia Threadneedle	147,623	0	For
Russell Investments	138,672	0	For
DRIEHAUS MUTUAL FUNDS	137,087	0	For
QUANTITATIVE MASTER SERIES LLC	127,843	0	For

Fund voting reports, all 109 managers: 36,973,668 for, 6,728 against, 13,167 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 268 asset managers voting on “Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described ” at PTC Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Janus Henderson	11,209,345	0	For
RTW INVESTMENTS, LP	7,746,415	0	For
State Street	4,110,340	0	For
Wellington	3,445,221	0	For
BlackRock	2,896,661	1,118	For
GEODE CAPITAL MANAGEMENT, LLC	2,217,194	0	For
Hood River Capital Management LLC	1,593,575	0	For
Fidelity	1,473,769	0	For
FRANKLIN ADVISERS INC	1,099,372	0	For
PICTET ASSET MANAGEMENT SA	1,080,589	0	For
DE Shaw	958,390	0	For
Palo Alto Investors LP	918,846	0	For
Charles Schwab	735,665	0	For
Invesco	718,347	0	For
JUPITER ASSET MANAGEMENT LTD	711,457	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	681,917	0	For
Vanguard	678,275	0	For
Nuveen	650,233	0	For
Northern Trust	640,082	0	For
Boston Partners	633,462	0	For
Ensign Peak Advisors, Inc	606,999	0	For
T. Rowe Price	577,324	0	For
PRINCIPAL GLOBAL INVESTORS	517,057	0	For
LORD, ABBETT & CO. LLC	516,933	0	For
MELLON INVESTMENTS Corp	512,828	0	For

Institutional-manager reports, all 268 managers: 53,744,988 for, 991,430 against, 34 abstained, 343 not voted. Showing the 25 largest; see all in the interactive database.

6. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR…

No official matchAUDIT-RELATED

99.9% of fund votes cast · no official result

FOR

Details: description as filed, votes by 109 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

The 109 asset managers below reported 36,931,534 for, 33,510 against, 13,167 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 36,931,534AGAINST: 33,510ABSTAIN: 13,167

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at PTC Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	10,913,384	2	For
BlackRock	8,919,225	0	For
Fidelity	3,183,248	0	For
State Street	2,643,965	146	For
JANUS INVESTMENT FUND	1,908,579	0	For
Manager Directed Portfolios	988,439	0	For
Charles Schwab	677,090	0	For
Invesco	663,622	0	For
TIAA	628,538	0	For
FRANKLIN STRATEGIC SERIES	488,115	0	For
Lord Abbett	385,360	0	For
Bridge Builder Trust	337,477	0	For
T. Rowe Price	324,181	0	For
Jackson National	299,094	0	For
TRUST FOR PROFESSIONAL MANAGERS	284,589	0	For
Hartford	262,612	0	For
Dimensional	225,758	0	For
Voya	220,168	0	For
Equitable	191,589	0	For
Loomis Sayles	176,905	0	For
Federated Hermes	148,171	0	For
Columbia Threadneedle	147,623	0	For
Russell Investments	138,672	0	For
DRIEHAUS MUTUAL FUNDS	137,087	0	For
QUANTITATIVE MASTER SERIES LLC	127,843	0	For

Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.

Largest PTC Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 82,882,024 shares outstanding at the time of that meeting.

Fund voting reports: top PTC Therapeutics, Inc. shareholders by shares voted on “Election of Four Class I Directors: Jerome B. Zeldis, M.D., Ph.D.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	13.17%
2	BlackRock	10.76%
3	Fidelity	3.84%
4	State Street	3.19%
5	JANUS INVESTMENT FUND	2.30%
6	Manager Directed Portfolios	1.19%
7	Charles Schwab	0.82%
8	Invesco	0.80%
9	TIAA	0.76%
10	FRANKLIN STRATEGIC SERIES	0.59%

Institutional-manager reports: top PTC Therapeutics, Inc. shareholders by shares voted on “Approval on a non-binding, advisory basis, of the Company's named executive officer…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Janus Henderson	13.52%
2	RTW INVESTMENTS, LP	9.35%
3	State Street	4.96%
4	Wellington	4.16%
5	BlackRock	3.50%
6	GEODE CAPITAL MANAGEMENT, LLC	2.68%
7	Hood River Capital Management LLC	1.92%
8	Fidelity	1.78%
9	FRANKLIN ADVISERS INC	1.33%
10	PICTET ASSET MANAGEMENT SA	1.30%

Reported PTC Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

PTC Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	15.62%	13F
Vanguard Group	10.62%	13F
RTW Investments L.P.	8.96%	DEF14A
JANUS HENDERSON GROUP PLC	8.68%	13G
Vanguard Portfolio Management	5.88%	13G
STATE STREET CORPORATION	5.07%	13G
Wellington Management	4.76%	13F
The Toronto-Dominion Bank	3.65%	13G
Michael Schmertzler	2.11%	DEF14A
D.E. Shaw	1.98%	13F

Percentages above are of 82,882,024 shares outstanding, as reported by PTC Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PTC Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At PTC Therapeutics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 347 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,022 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. PTC Therapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approval on a non-binding, advisory basis, of the Company's named executive officer… — the reporting funds and managers cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

PTC Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.